Submission of proposed biosimilar supported by comprehensive package; aims to expand treatment access for people with multiple sclerosis in US and EU Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that can drastically a…
Entries by https://www.sandoz.com/rss/feeds/news/media-releases.xml
Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand access to medicine for patients with chronic immune-mediated inflammatory diseases Sandoz is comm…
Ad hoc announcement pursuant to Art. 53 LRQ2 sales grew +5% cc1 (-1% USD)Innovative Medicines (IM) sales grew +5% cc (-1% USD); strong performance of key growth brands including Entresto (+33% cc), Kesimpta (+270% cc), Cosentyx (+12% cc), Kisqali (+43%…
Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics studyAdalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced yet familiar experience for patientsSubmission builds o…
Dimethyl fumarate HEXAL® is bioequivalent to the originator product 1,2,3Additional 196 pack size reduces co-payment burden for patientsBasel, June 10, 2022 — Sandoz expands its portfolio and today announces the launch of the generic drug Dimethyl fuma…
Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders Action Plan will provide roadmap and tools to improve approvability, accessibility, ac…
Dr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA)The Alliance brings together about 100 life science companies / associations in search of sustainabl…
Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF),1 a progressive disease that causes irreversible lung scarring and makes it difficult to breathe2Approximately 140,000 Americans live with IPF, a rare disease with no cure, and 50,000 new…
Ad hoc announcement pursuant to Art. 53 LRQ1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD)Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core operating income +5% (cc, 0% USD)Strong performance of key growth br…
Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1Ocular hypertension affects over 5% of all adults2; the eye does not properly drain fluid, causing eye pressure to buil…